Dionysis S. Nikolopoulos

Stockholm, AB, Sweden

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 66 publications

IgG glycosylation dynamics in active lupus nephritis during the first year of immunosuppressive therapy.

IgG glycosylation dynamics in active lupus nephritis during the first year of immunosuppressive therapy.

Journal: Frontiers in immunology
Published: May 20, 2026

Optical Spectral Transmission Imaging in Patients with Osteoarthritis: A Comparative Study with Joint Ultrasound and Clinical Markers.

Optical Spectral Transmission Imaging in Patients with Osteoarthritis: A Comparative Study with Joint Ultrasound and Clinical Markers.

Journal: Rheumatology and therapy
Published: April 10, 2026

Unique brain mechanisms in early events in SLE with diffuse neuropsychiatric disease (NPSLE): Implications for the management.

Unique brain mechanisms in early events in SLE with diffuse neuropsychiatric disease (NPSLE): Implications for the management.

Journal: Lupus
Published: March 14, 2026

Anti-DFS70 antibodies in systemic lupus erythematosus and lupus nephritis: revisiting their clinical implications.

Anti-DFS70 antibodies in systemic lupus erythematosus and lupus nephritis: revisiting their clinical implications.

Journal: Autoimmunity reviews
Published: February 05, 2026

Old and new autoantibodies in systemic lupus erythematosus.

Old and new autoantibodies in systemic lupus erythematosus.

Journal: Expert review of clinical immunology
Published: February 04, 2026

Soluble urokinase plasminogen activator receptor (suPAR) is associated with intrarenal chronicity features on diagnostic and repeat kidney biopsies in lupus nephritis.

Soluble urokinase plasminogen activator receptor (suPAR) is associated with intrarenal chronicity features on diagnostic and repeat kidney biopsies in lupus nephritis.

Journal: Seminars in arthritis and rheumatism
Published: January 31, 2026

Glycomic Profiles of IgG, C3 and Alpha-1-Acid Glycoprotein (AGP) Before and One Year After Treatment for Active Lupus Nephritis.

Glycomic Profiles of IgG, C3 and Alpha-1-Acid Glycoprotein (AGP) Before and One Year After Treatment for Active Lupus Nephritis.

Journal: Cells
Published: January 31, 2026

A data-driven, weighted flare score that accurately predicts organ damage in systemic lupus erythematosus.

A data-driven, weighted flare score that accurately predicts organ damage in systemic lupus erythematosus.

Journal: Annals of the rheumatic diseases
Published: January 30, 2026

Belimumab outperforms placebo for attainment of modified DORIS remission and LLDAS without the glucocorticoid component: a post hoc analysis of five phase III SLE trials.

Belimumab outperforms placebo for attainment of modified DORIS remission and LLDAS without the glucocorticoid component: a post hoc analysis of five phase III SLE trials.

Journal: RMD open
Published: December 09, 2025

Lessons Learnt from the Belimumab Trials in Systemic Lupus Erythematosus.

Lessons Learnt from the Belimumab Trials in Systemic Lupus Erythematosus.

Journal: International journal of molecular sciences
Published: November 25, 2025

Peripheral blood transcriptomic analysis of patients with rheumatoid arthritis associated interstitial lung disease reveals: distinct molecular signature with evidence of humoral and myeloid immunity.

Peripheral blood transcriptomic analysis of patients with rheumatoid arthritis associated interstitial lung disease reveals: distinct molecular signature with evidence of humoral and myeloid immunity.

Journal: Arthritis research & therapy
Published: October 27, 2025

Untargeted breathomics identifies metabolic signatures of immune activity, intestinal integrity, and fatigue in systemic lupus erythematosus.

Untargeted breathomics identifies metabolic signatures of immune activity, intestinal integrity, and fatigue in systemic lupus erythematosus.

Journal: Annals of the rheumatic diseases
Published: July 08, 2025
Showing 1-12 of 66

Last Updated: 09/26/2026